- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging Roles of ALK in Immunity and Insights for Immunotherapy
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 2, Pages 426
Publisher
MDPI AG
Online
2020-02-24
DOI
10.3390/cancers12020426
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting ALK in Cancer: Therapeutic Potential of Proapoptotic Peptides
- (2019) Arthur Aubry et al. Cancers
- LDK378 improves micro- and macro-circulation via alleviating STING-mediated inflammatory injury in a Sepsis rat model induced by Cecal ligation and puncture
- (2019) Weiwei Ge et al. Journal of Inflammation-London
- NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma
- (2019) Vijay Kumar Singh et al. OncoImmunology
- A kinome-wide screen using a NanoLuc LATS luminescent biosensor identifies ALK as a novel regulator of the Hippo pathway in tumorigenesis and immune evasion
- (2019) Kazem Nouri et al. FASEB JOURNAL
- PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma
- (2019) Jing Shen et al. MODERN PATHOLOGY
- ALK and RET inhibitors promote HLA class I antigen presentation and unmask new antigens within the tumor immunopeptidome
- (2019) Claire Y Oh et al. Cancer Immunology Research
- ALK is required for NLRP3 inflammasome activation in macrophages
- (2018) Bibo Zhang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)
- (2018) David R. Spigel et al. Journal of Thoracic Oncology
- A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations
- (2018) Jugmohit S. Toor et al. Frontiers in Immunology
- Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC).
- (2018) Dong-Wan Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Avelumab (anti–PD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC: Phase 1b results from JAVELIN Lung 101.
- (2018) Alice Tsang Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer
- (2018) Su-Jung Kim et al. Cancer Research and Treatment
- Blood cytokine concentrations in pediatric patients with anaplastic lymphoma kinase-positive anaplastic large cell lymphoma
- (2017) Fabian Knörr et al. HAEMATOLOGICA
- Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase
- (2017) Alec J. Walker et al. MOLECULAR THERAPY
- An immunogenic personal neoantigen vaccine for patients with melanoma
- (2017) Patrick A. Ott et al. NATURE
- ALKFusions in a Wide Variety of Tumor Types Respond to Anti‐ALK Targeted Therapy
- (2017) Jeffrey S. Ross et al. ONCOLOGIST
- Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma
- (2017) Charlotte Rigaud et al. PEDIATRIC BLOOD & CANCER
- ALK is a therapeutic target for lethal sepsis
- (2017) Ling Zeng et al. Science Translational Medicine
- Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer
- (2017) Mark M. Awad et al. Oncotarget
- Blood cytokine concentrations in pediatric patients with anaplastic lymphoma kinase-positive anaplastic large cell lymphoma
- (2017) Fabian Knörr et al. HAEMATOLOGICA
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
- (2016) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK
- (2016) Christine Damm-Welk et al. Journal of Cancer
- Abstract A021: Development of an ALK vaccine to treat ALK-rearranged non-small cell lung cancers
- (2016) Rafael B. Blasco Cancer Immunology Research
- 351OInduction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non–small cell lung cancer
- (2015) K. Ota et al. ANNALS OF ONCOLOGY
- Targeted Disruption of ALK Reveals a Potential Role in Hypogonadotropic Hypogonadism
- (2015) Barbara Witek et al. PLoS One
- Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand–receptor interactions
- (2015) Andrey V. Reshetnyak et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase
- (2015) Jikui Guan et al. eLife
- Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors
- (2015) C. Voena et al. Cancer Immunology Research
- Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients
- (2015) Shaodong Hong et al. OncoImmunology
- PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
- (2014) A D'Incecco et al. BRITISH JOURNAL OF CANCER
- ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma
- (2014) Scott C. Bresler et al. CANCER CELL
- ALKin Lung Cancer: Past, Present, and Future
- (2013) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer
- (2012) H. Ren et al. CANCER RESEARCH
- Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis
- (2012) L Mussolin et al. LEUKEMIA
- Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma
- (2012) E L Carpenter et al. ONCOGENE
- ALK-Activating Homologous Mutations in LTK Induce Cellular Transformation
- (2012) J. Devon Roll et al. PLoS One
- Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk
- (2010) K. Ait-Tahar et al. BLOOD
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Renal cell carcinoma with novel VCL–ALK fusion: new representative of ALK-associated tumor spectrum
- (2010) Larisa V Debelenko et al. MODERN PATHOLOGY
- Studies of Phosphoproteomic Changes Induced by Nucleophosmin-Anaplastic Lymphoma Kinase (ALK) Highlight Deregulation of Tumor Necrosis Factor (TNF)/Fas/TNF-related Apoptosis-induced Ligand Signaling Pathway in ALK-positive Anaplastic Large Cell Lymphoma
- (2010) Fang Wu et al. MOLECULAR & CELLULAR PROTEOMICS
- Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non-Small Cell Lung Cancers
- (2009) E. Lin et al. MOLECULAR CANCER RESEARCH
- Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor
- (2009) D C Stylianou et al. ONCOGENE
- Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma
- (2008) J Dien Bard et al. LEUKEMIA
- Kinetics of humoral response to ALK and its relationship with minimal residual disease in pediatric ALCL
- (2008) L Mussolin et al. LEUKEMIA
- Immune privilege or privileged immunity?
- (2008) J V Forrester et al. Mucosal Immunology
- The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination
- (2008) Roberto Chiarle et al. NATURE MEDICINE
- Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
- (2008) M. Marzec et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started